Dr Mihriban Tuna appointed Chief Scientific Officer at new biotechnology start-up - News & insight - Cambridge Judge Business School
JP Morgan 2022 – day one sees healthy deal flow from biopharma | Evaluate
Adaptate Biotherapeutics appoints Dr Mihriban Tuna as Chief Scientific Officer | The Scientist Magazine®
GammaDelta spins out new company Adaptate Biotherapeutics
Milestone: White City Place W12
Adaptate Biotherapeutics formed to develop antibody-based therapies that modulate gamma delta T-cells | Business Wire
Insights+: Key Takeaways of J.P. Morgan Healthcare Conference 2022 Based on Therapeutic Areas
Oncologie : Takeda va acquérir Adaptate Biotherapeutics
Adaptate Biotherapeutics - Crunchbase Company Profile & Funding
Adaptate Biotherapeutics Formed To Develop T-cell Modulating Antibody-based Therapies | Technology Networks
Adaptate Biotherapeutics | LinkedIn
Takeda aquiere Adaptate Biotherapeutics | Pharmabiz.NET
Adaptate Biotherapeutics raises $18 million in Series A2 funding | Cambridge Network
Takeda en passe d'acquérir Adaptate Biotherapeutics pour développer de nouvelles thérapies associées aux engageurs de cellules T Gamma Delta (γδ) ciblant les tumeurs solides | Business Wire
Takeda to acquire Adaptate for novel T-cell engager technology
Andy Chi on LinkedIn: Takeda to Acquire Adaptate Biotherapeutics to Develop Novel GammaDelta…
GammaDelta Therapeutics Spins Out Adaptate Bio to Develop Gammadelta T-Cells | BioSpace
Adaptate Biotherapeutics Company Profile, information, investors, valuation & Funding
IONTAS and Adaptate Biotherapeutics collaborate to identify optimised antibodies for novel cancer targets | World Pharma Today
IONTAS and Adaptate Biotherapeutics Collaborate to Identify Optimized Antibodies for Novel Cancer Targets | Lab Manager
Adaptate Biotherapeutics | LinkedIn
Japan's Takeda buys Adaptate Biotherapeutics to strengthen immuno-oncology portfolio
IONTAS and Adaptate Biotherapeutics collaborate to identify optimised antibodies for novel cancer targets
Takeda ups portfolio with Adaptate buy - BioProcess InsiderBioProcess International
Takeda adquiere Adaptate Biotherapeutics para desarrollar nuevas terapias de activación de células T gamma delta dirigidas a tumores sólidos
Adaptate Biotherapeutics Company Profile: Valuation, Investors, Acquisition | PitchBook
